working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
let's go to $ 0.35-0.43 ... in principle
Flu vaccine exists
Do you remember anything?
"I have been told by a friend that treatment for his colonic disease requires a 4 hour clinic visit with an IV and the EOB report indicates about $12K for the treatment every 8 weeks or so. He indicates that taking a pill with limited side effects would be a significant benefit for many and that there are several people for which the current treatments do not work. This seems like the type of news that would have BPs clamoring to get involved with the B franchise considering the potential market. I would love to hear some of the ongoing backroom discussions and especially what LW thinks of today's results."
Chemdeps
Another success for BDD's patented OralogiK™ technology with positive clinical results for colon targeting formulation.https://t.co/YUeT9CgMLC#colontargeting #drugdelivery #pharmaceuticals #ibs #ulcerativecolitis pic.twitter.com/mqJylZHnA2
— BDD (@BDD_Pharma) February 13, 2020
Novartis, Bdd Pharma...IPIX
BOOOOMMMM 0,10
IPIX
0,90$
IPIX
new deal coming, booommmm
IPIX
NEWS 0.10$ are here
IPIX
0.10$ on the way. IPIX
0.10$ is here. IPIX
load the ship, there is little left
means: we have something to sell and LW will sell it
IPIX 0.078$
you mean today?
because we have been a few months ...
and lower the price?
IPIX -30%
no, just resignation
compared to who?
this year in the US a total of 10 national holidays,
this year in Spain a total of 10 national holidays,
this year in Italy a total of 12 national holidays,
this year in France a total of 11 national holidays,
working hours in the US 40 hours per week,
in Spain, Italy, 40 hours a week,
in germany 38 to 40 hours per week,
there is no objective data to suggest that we have to wait until 2020 for any reason,
except that only 23 days of 2019 are missing
correct, LOL
TIC TAC, TIC TAC,
IPIX
IPIX Laser-Focused on IBD and OM as Fastest Path to Revenue
2 Clinical Trials in IBD Expected in 2020
Company Exploring Partners in OM for Phase 3 Trial
My Fellow IPIX Shareholders,
Seeing the acquisition of The Medicines Company by Novartis for $9.7 billion this week reminds me of the path they took to exit the infectious disease business through the sale of the unit to Melinta Therapeutics in November 2017 and use the money towards another direction. As we learned, infectious disease is a notoriously onerous and expensive indication for developing new drugs. The Medicines Company exited that space to focus on the more lucrative cardiovascular space, namely its experimental cholesterol-lowering drug Inclisiran that was the prize in the Novartis acquisition.
Melinta’s stock has suffered ever since the acquisition, which we think speaks to the infectious disease environment at this moment, particularly ABSSSI (Acute Bacterial Skin and Skin Structure Infection). This underscores our decision to shelf Brilacidin in the infectious disease space for the time being as we focus on what we believe are much better risk/reward opportunities in Inflammatory Bowel Disease (IBD) and Oral Mucositis (OM).
Make no mistake about it, 100% of our efforts are being devoted to the shortest path to revenue with the lowest risk profile. That is IBD and OM.
Based upon our discussions with potential partners and interested parties, it is clear that IBD is the area of greatest demand due to market size and need for new alternatives. To that point, IBD presents an enormous opportunity and we feel our team has made significant headway heading into 2020.
Earlier this year, we set a goal to advance Brilacidin into two clinical trials for IBD by mid-2020 with the understanding that we needed to partner to have the resources to meet our goal. Our new European partner provided us with some upfront cash, with payments owed for meeting developmental milestones along with future royalties on sales, which we believe could net us millions of dollars in revenue annually should the drug ultimately be commercialized by our partner for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Importantly, they are shouldering all developmental costs for those indications. We also get the added benefit of more clinical data on Brilacidin from their studies.
We are working diligently to initiate our own company-sponsored studies for Ulcerative Colitis (UC), which, as we have said before, is a much larger patient population and market size than UP/UPS. The Brilacidin for the planned UC study is now in the hands of our manufacturing partner to be formulated for targeted delivery to the colon and documents have been submitted to health authorities for the study. We hope that one day we will look back at the decision to aggressively pursue IBD as the watershed moment for the franchise and our company.
Oral Mucositis
We are engaged in licensing discussions with potential business partners for Brilacidin for the prevention of severe oral mucositis. In addition, we retained a prominent advisory company to help us with plans for this asset. We believe there is a tremendous unaddressed market that has the ability to generate billions of dollars in lifetime revenue for a company that can successfully develop a safe and highly efficacious, FDA-approved drug for OM. If we don’t receive an appropriate licensing offer, we will seek an internal pathway to begin advanced late stage clinical trials.
"i. Number of Beneficial Owners holding at least 100 shares: Number as of Date Approximately 10,000 as of June 30, 2019"
hitting the hard ASK
IPIX
IPIX NEWS:
BEVERLY, MA – November 25, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company received notification from the Food and Drug Administration (FDA) that a waiver has been granted eliminating the need to study Brilacidin, for the prevention of Severe Oral Mucositis in Head and Neck Cancer (HNC) patients receiving chemoradiation, in pediatric populations.
The granting of this waiver now enables the Company to develop Brilacidin in a more focused manner in adult patient populations where Oral Mucositis has the greatest impact.
In other news, the Company will provide shortly an update on continuing clinical development of Brilacidin for Inflammatory Bowel Disease, including the status of planned clinical work in Ulcerative Proctitis/Ulcerative Proctosigmoiditis.
a hypothesis
but you cannot dilute $ 300 at this price and with this daily volume,
the PPS would go to 0000000
the income outlook would be very low
average?
How many times do we have to average?
average continue to have a losing position ...
but with more money invested
in a market like OTC that's very dangerous